Harrow, Inc. Notes Assumed
Harrow, Inc. (HROW) reported Notes Assumed of $908.00 thousand for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:NotesAssumed1 · last filed 2021-11-09
- 2021-09-30: Notes Assumed 9 month $908.00K.
| Period end | Notes Assumed 9 month |
|---|---|
| 2021-09-30 | $908.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |